The role of proprotein convertase subtilisin/kexin 9 (PCSK9) in macrophage activation: a focus on its LDL receptor-independent mechanisms
Authors:
Open Access
- 1 August 2024
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Cardiovascular Medicine
- Vol. 11, 1431398
Abstract
Recent clinical trials demonstrated that proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors reduce cardiovascular events without affecting systemic inflammation in the patients with coronary artery disease, as determined by high sensitivity C-reactive protein (CRP) levels. However, its pro-inflammatory effects in cardiovascular disease in humans and experimental animals beyond the traditional cholesterol receptor-dependent lipid metabolism have also called attention of the scientific community. PCSK9 may target receptors associated with inflammation other than the low-density lipoprotein receptor (LDLR) and members of the LDLR family. Accumulating evidence suggests that PCSK9 promotes macrophage activation not only via lipid-dependent mechanisms, but also lipid-independent and LDLR-dependent or -independent mechanisms. In addition to dyslipidemia, PCSK9 may thus be a potential therapeutic target for various pro-inflammatory diseases.Keywords
This publication has 51 references indexed in Scilit:
- Evidence of an anti-inflammatory effect of PCSK9 inhibitors within the human atherosclerotic plaqueAtherosclerosis, 2023
- Intensive lipid lowering agents and coronary atherosclerosis: Insights from intravascular imagingAmerican Journal of Preventive Cardiology, 2022
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial InfarctionJAMA, 2022
- New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathwayAtherosclerosis, 2017
- Effect of Evolocumab on Progression of Coronary Disease in Statin-Treated PatientsJAMA, 2016
- A single injection of gain-of-function mutant PCSK9 adeno-associated virus vector induces cardiovascular calcification in mice with no genetic modificationAtherosclerosis, 2016
- GRP94 Regulates Circulating Cholesterol Levels through Blockade of PCSK9-Induced LDLR DegradationCell Reports, 2015
- Local effects of human PCSK9 on the atherosclerotic lesionThe Journal of Pathology, 2015
- Proprotein convertase subtilisin kexin type 9 (PCSK9) secreted by cultured smooth muscle cells reduces macrophages LDLR levelsAtherosclerosis, 2012
- The LDLR deficient mouse as a model for aortic calcification and quantification by micro-computed tomographyAtherosclerosis, 2011